PPT-Effects of intravenous iron in chronic kidney disease and cardiac function

Dr Ahmed Zeidan Prof Sunil Bhandari Iron and the Heart EudraCT Number 201400413316 Aims Background and Rationale for iron therapy in CKD Hypothesis Trial Design Objectives Primary . CKD. Dialysis. Renal Transplant. Bones can break, muscles can atrophy, glands can loaf, even the brain can go to sleep without immediate danger to survival. But -- should kidneys fail.... neither bone, muscle, nor brain could carry on.. Kevin Harley, M.D.. Assistant Clinical Professor. Department of Medicine. Division of Nephrology & Hypertension. UC Irvine Medical Center. Objectives. Review Definition of CKD and its classification. Epidemiology. CKD affects about 26 million people in the US. Approximately 19 million adults are in the early stages of the disease . On the rise do to increasing prevalence of diabetes and hypertension. Epidemiology. CKD affects about 26 million people in the US. Approximately 19 million adults are in the early stages of the disease . On the rise do to increasing prevalence of diabetes and hypertension. Chronic Kidney Disease: Detection and Management in Primary Care Julia Scialla, MD, MHS, FASN Associate Professor of Medicine and Public Health Sciences University of Virginia Adjunct Associate Professor of Medicine Chronic Kidney Failure Done by : Resources : Objectives : Extra Book Notes Important Golden Notes Differentiate Chronic kidney disease-CKD from Acute Kidney Injury-AKI. Dr. T. A. L. . Dlamini. Specialist Physician and . Nephrologist. Talk overview . Kidney function. Assessing kidney function. Chronic kidney disease (CKD). Benefits of early detection . Conclusion and take home message . 2 DIURETICS also known as 147WATER PILLS148 PURPOSES SPECIFIC MEDICATONS POSSIBLE HARMFUL EFFECTS PERSONAL EFFORTS TO ENHANCE THERAPY Increase salt sodium elimination by the kidneys Decrease leg lun Andrew . Narva. , MD, FASN & . Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. Andrew . Narva. , MD, FASN. No financial disclosures/conflicts of interest. Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. Namita Singh, MD, FASN. Year 2021. DISCLOSURES. I have no financial relationships with commercial interests to disclose.. This presentation does not include discussion of off-label or investigational use. . Chronic . c. are . Training . For . district . hospital . Nurses . in . Rwanda . 2013. Session 1: Defining chronic kidney disease. By the end of this Session, participants will be able to:. Screen for chronic kidney disease. . Structural . or functional abnormalities of the kidneys for . >. 3 months. . from early to late-stage disease, . Chronic Kidney Disease. as . manifested by either:. 1. Kidney . damage, with or without decreased GFR, as . Konstantia. Ass. Prof. of Nephrology D.U.TH.. Reduced quality of life . van Haalen et al. BMC Nephrology 2020. Worse renal survival. Lamerato et al. BMC Nephrology 2022. Increase in morbidity and mortality. By. Mostafa. . Abd_Elsalam,MD. MUH,MNDU. Definitions. K/DOQI, 2002. Chronic kidney disease . Epidemiology of chronic kidney disease. . U.S. Renal Data System (2013) USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease.